Neumora Therapeutics Inc.... (NMRA)

1.05

-0.05 (-4.55%)

At close: Mar 28, 2025, 2:02 PM

Neumora Therapeutics Common Stock Cash Flow Statement

Table Mode

Year	FY24	FY23	FY22	FY21	FY20
Net Income	-243.79M	-235.93M	-130.9M	-237.31M	-99.27M
Depreciation & Amortization	n/a	668K	594K	538K	105K
Stock-Based Compensation	39.99M	17.24M	8.3M	4.27M	1.68M
Other Working Capital	19.76M	-8.32M	-5.7M	-202K	1.55M
Other Non-Cash Items	-1.77M	63.64M	15.35M	158.09M	70.77M
Deferred Income Tax	n/a	n/a	-1.28M	-53K	3.08M
Change in Working Capital	22.64M	-8.9M	-6.95M	-961K	-3.12M
Operating Cash Flow	-182.94M	-163.28M	-114.9M	-75.42M	-26.76M
Capital Expenditures	n/a	-117K	-511K	-817K	-1.3M
Acquisitions	n/a	n/a	n/a	n/a	n/a
Purchase of Investments	n/a	-109.07M	-226.37M	n/a	n/a
Sales Maturities Of Investments	n/a	178.17M	71.87M	n/a	n/a
Other Investing Acitivies	-70.56M	-4.59M	-13M	n/a	-9.94M
Investing Cash Flow	-70.56M	64.39M	-168.01M	-817K	-11.24M
Debt Repayment	n/a	n/a	n/a	n/a	55.91M
Common Stock Repurchased	n/a	-491K	n/a	n/a	-2K
Dividend Paid	n/a	n/a	n/a	n/a	n/a
Other Financial Acitivies	7.91M	-948K	115.74M	292.55M	171.01M
Financial Cash Flow	21.6M	231.94M	115.74M	293.51M	230.1M
Net Cash Flow	-231.89M	133.04M	-167.17M	217.27M	192.1M
Free Cash Flow	-182.94M	-163.4M	-115.41M	-76.24M	-28.06M